ஜாஸ் பார்மா News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜாஸ் பார்மா. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜாஸ் பார்மா Today - Breaking & Trending Today

The Cannabis Industry 2.0: Setting the Stage For 2021 And Beyond


By Matthew Anderson and Gregory Frye
The Cannabis Industry today is not what it was 18 months ago. The landscape is evolving fast, and COVID-19 has acted as a catalyst, speeding up the inevitable. 
Mergers and acquisitions, stock market turbulence, fluctuating market prices, businesses struggling and failing, investors getting burned – combined with new markets coming online, greater de-stigmatization, and increased consumer demand. 
All these elements are mixing together to create an intense environment where the wheat is separated from the chaff, and only the strongest, smartest operators survive.
And yet a collaborative approach is more important now than ever. Federal legalization or decriminalization is coming to the U.S., and it is going to flip the industry upside down.  ....

Matthew Anderson , Gregory Frye , International Cannabis Council , Green Thumb Industries , Gw Pharmaceuticals , Cannabis Industry , Controlled Substances , Industry Stalwarts , Jazz Pharma , Market Turbulence , Nathan Mison , International Cannabis , North Star , Vanguard Scientific , Buyer Where They , Understanding Where , மேத்யூ ஆண்டர்சன் , கிரெகொரி வறுக்கவும் , பச்சை கட்டைவிரல் தொழில்கள் , க்வ் மருந்துகள் , கஞ்சா தொழில் , ஜாஸ் பார்மா , நாதன் மிசோன் , சர்வதேச கஞ்சா , வடக்கு நட்சத்திரம் , வான்கார்ட் அறிவியல் ,

BIIB Pulls Plug On Parkinson's Drug, JAZZ Acquires GWPH, NBIX Ends Deal With VYGR, TYME Flies


(2)
WESTON (dpa-AFX) - Today s Daily Dose brings you news about Biogen pulling the plug on a potential Parkinson s drug, Jazz Pharma acquiring GW Pharmaceuticals, Neurocrine terminating its agreement with Voyager related to Parkinson s disease drug development, and Vaxart s phase I study results of oral COVID-19 tablet vaccine candidate.
Read on.
1. Biogen throws in the towel on potential Parkinson s Drug
Biogen Inc. (BIIB) has discontinued the development of BIIB054 (Cinpanemab), a potential Parkinson s drug, following the failure of that compound in a phase II study.
The phase II study of BIIB054, dubbed SPARK, has not met its primary or secondary endpoints. The company has recognized an impairment charge of approximately $75.4 million during the fourth quarter of 2020, as a result of terminating BIIB054. ....

United States , Neurocrine Biosciences Inc , Cassava Sciences Inc , Voyager Therapeutics Inc , Jazz Pharmaceuticals , Biogen Inc , Ocugen Inc , Anavex Life Sciences Corp , Gw Pharmaceuticals , Tyme Technologies Inc , Clene Inc , Vaxart Inc , Daily Dose , Jazz Pharma , Loosens Purse , American Depositary Share , Lennox Gastaut Syndrome , Dravet Syndrome , Tuberous Sclerosis Complex , Ends Parkinson , Voyager Therapeutics , Soars On New Patent For , Reports Phasei Trial Results , Life Sciences , ஒன்றுபட்டது மாநிலங்களில் , கசவா அறிவியல் இன்க் ,